A randomised, open, controlled pilot study to investigate the efficacy and safety of Buparid/PARI SINUS versus Budes Nasal Spray in the therapy of Chronic Rhinosinusitis (CRS) with polyposis nasi in adult patients
Phase of Trial: Phase III
Latest Information Update: 13 Apr 2017
At a glance
- Drugs Budesonide (Primary)
- Indications Rhinosinusitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors PARI Pharma GmbH
- 12 Dec 2016 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
- 12 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 09 Sep 2016 Status and study dates are kept as per NCT as it is recently updated.